Mark E. Mailliard, Mary E. Capadano, Matthew J. Hrnicek, Richard K. Gilroy, James M. Gulizia – 29 July 2009 – Between March 2000 and July 2001, at least 99 persons acquired a hepatitis C virus genotype 3a (HCV‐3a) infection in an oncology clinic. This nosocomial HCV outbreak provided an opportunity to examine the subsequent clinical course in a well‐defined cohort. This was a retrospective/prospective observational study of the short‐term significant health outcomes of a large, single‐source, patient‐to‐patient HCV‐3a outbreak.

Shelly C. Lu, Komal Ramani, Xiaopeng Ou, Mark Lin, Victor Yu, Kwangsuk Ko, Ryan Park, Teodoro Bottiglieri, Hidekazu Tsukamoto, Gary Kanel, Samuel W. French, José M. Mato, Rex Moats, Edward Grant – 29 July 2009 – Hepatocellular carcinoma (HCC) remains a common cancer worldwide that lacks effective chemoprevention or treatment. Chronic liver disease often leads to impaired hepatic S‐adenosylmethionine (SAMe) biosynthesis, and mice with SAMe deficiency develop HCC spontaneously. SAMe is antiapoptotic in normal hepatocytes but proapoptotic in cancerous hepatocytes.

Alessia Omenetti, Wing‐Kin Syn, Youngmi Jung, Heather Francis, Alessandro Porrello, Rafal P. Witek, Steve S. Choi, Liu Yang, Marlyn J. Mayo, M. Eric Gershwin, Gianfranco Alpini, Anna Mae Diehl – 29 July 2009 – The mechanisms mediating hepatic accumulation of inflammatory cells in cholestatic liver disease remain enigmatic. Our thesis is that Hedgehog (Hh) pathway activation promotes hepatic accumulation of immune cells that interact with cholangiocytes.

Laura Elisa Buitrago‐Molina, Deepika Pothiraju, Jutta Lamlé, Silke Marhenke, Uta Kossatz, Kai Breuhahn, Michael P. Manns, Nisar Malek, Arndt Vogel – 29 July 2009 – In this study, everolimus (RAD001) was used to determine the role of mammalian target of rapamycin (mTOR) in hepatocarcinogenesis. We show that RAD001 effectively inhibits proliferation of hepatocytes during chronic liver injury. Remarkably, the ability of RAD001 to impair cell cycle progression requires activation of the DNA damage response; loss of p53 significantly attenuates the antiproliferative effects of mTOR inhibition.

Xiaoying Zhang, Shanrong Liu, Tingsong Hu, Shupeng Liu, Ying He, Shuhan Sun – 29 July 2009 – It is increasingly clear that hepatocellular carcinoma (HCC) has a distinct microRNA (miRNA) expression profile that is involved in malignancy; however, little is known about how functional miRNA modulates the metastasis of hepatitis B virus (HBV)‐related HCC (HBV‐HCC). In the present study, we demonstrate that the levels of miRNA‐143 (miR‐143) are dramatically increased in metastatic HBV‐HCC of both p21‐HBx transgenic mice and HCC patients.

29 June 2009

Rosa M. Valadao, Norah A. Terrault – 26 June 2009

Ramadan M. El Gharbawy, Lee J. Skandalakis, Thomas G. Heffron, John E. Skandalakis – 26 June 2009

Renato Romagnoli, Damiano Patrono, Stefano Mirabella, Paolo Strignano, Alessandro Ricchiuti, Gianluca Paraluppi, Alessandro Franchello, Francesco Lupo, Piero Borasio, Mauro Salizzoni – 26 June 2009

Paul J. Thuluvath, Anurag Maheshwari, Nimisha P. Thuluvath, Geoffrey C. Nguyen, Dorry L. Segev – 26 June 2009 – It has been suggested that hepatitis C virus (HCV) patients with hepatocellular carcinoma (HCC) may have worse outcomes after liver transplantation (LT) because of more aggressive tumor biology. In this study, we determined the post‐LT survival of HCC patients with and without HCV using United Network for Organ Sharing data from January 1994 to March 2008. Patients with HCC were stratified into HCV (HCC‐HCV) and non‐HCV (HCC–non‐HCV) groups.